المؤلفون: Camidge, D. Ross, Ahn, Myung-Ju, Yang, James C. H., Han, Ji-Youn, Hochmair, Maximilian J., Felip Font, Enriqueta, Kim, Hye Ryun

المساهمون: Institut Català de la Salut, Camidge DR Department of Medicine, University of Colorado Cancer Center, Aurora, Colorado. Kim HR Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Ahn MJ Division of Hematology-Oncology, Samsung Medical Center, Seoul, South Korea. Yang JCH Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. Han JY Department of Precision Medicine, National Cancer Center, Gyeonggi, South Korea. Hochmair MJ Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria. Felip E Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Pulmons - Càncer - Tractament, Avaluació de resultats (Assistència sanitària), DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia

وصف الملف: application/pdf

العلاقة: Journal of Thoracic Oncology;16(12); https://doi.org/10.1016/j.jtho.2021.07.035Test; Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. J Thorac Oncol. 2021 Dec 1;16(12):2091–108.; https://hdl.handle.net/11351/7790Test; 000721176100017

الإتاحة: https://doi.org/10.1016/j.jtho.2021.07.035Test
https://hdl.handle.net/11351/7790Test

المؤلفون: Camidge, D. Ross, Ahn, Myung-Ju, Yang, James C. H., Han, Ji-Youn, Hochmair, Maximilian J., Felip Font, Enriqueta, Kim, Hye Ryun

المساهمون: Institut Català de la Salut, Camidge DR University of Colorado Cancer Center, Aurora, CO. Kim HR Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Ahn MJ Samsung Medical Center, Seoul, South Korea. Yang JCH National Taiwan University Hospital, Taipei, Taiwan. Han JY National Cancer Center, Goyang, South Korea. Hochmair MJ Department of Respiratory and Critical Care Medicine, Krankenhaus Nord–Klinik Floridsdorf, Vienna, Austria. Felip E Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Pulmons - Càncer - Tractament, Medicaments antineoplàstics - Ús terapèutic - Eficàcia, DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome::Progression-Free Survival, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento::supervivencia libre de progresión

وصف الملف: application/pdf

العلاقة: Journal of Clinical Oncology;38(31); https://doi.org/10.1200/JCO.20.00505Test; Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020 Nov 1;38(31):3592–603.; https://hdl.handle.net/11351/6346Test; 000588411100004

الإتاحة: https://doi.org/10.1200/JCO.20.00505Test
https://hdl.handle.net/11351/6346Test